Your browser doesn't support javascript.
loading
Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides.
Bost, Jeremy P; Ojansivu, Miina; Munson, Michael J; Wesén, Emelie; Gallud, Audrey; Gupta, Dhanu; Gustafsson, Oskar; Saher, Osama; Rädler, Julia; Higgins, Stuart G; Lehto, Taavi; Holme, Margaret N; Dahlén, Anders; Engkvist, Ola; Strömstedt, Per-Erik; Andersson, Shalini; Edvard Smith, C I; Stevens, Molly M; Esbjörner, Elin K; Collén, Anna; El Andaloussi, Samir.
Afiliação
  • Bost JP; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14157, Sweden. jeremy.bost@ki.se.
  • Ojansivu M; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden.
  • Munson MJ; Advanced Drug Delivery, Pharmaceutical Sciences, Biopharmaceutical R&D, AstraZeneca, Mölndal, 43150, Sweden.
  • Wesén E; Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, 41296, Sweden.
  • Gallud A; Advanced Drug Delivery, Pharmaceutical Sciences, Biopharmaceutical R&D, AstraZeneca, Mölndal, 43150, Sweden.
  • Gupta D; Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, 41296, Sweden.
  • Gustafsson O; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14157, Sweden.
  • Saher O; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14157, Sweden.
  • Rädler J; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14157, Sweden.
  • Higgins SG; Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, 11562, Egypt.
  • Lehto T; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14157, Sweden.
  • Holme MN; Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom.
  • Dahlén A; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14157, Sweden.
  • Engkvist O; Institute of Technology, University of Tartu, Nooruse 1, Tartu, 50411, Estonia.
  • Strömstedt PE; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden.
  • Andersson S; Discovery Sciences, R&D, AstraZeneca, Gothenburg, 43150, Sweden.
  • Edvard Smith CI; Discovery Sciences, R&D, AstraZeneca, Gothenburg, 43150, Sweden.
  • Stevens MM; Discovery Sciences, R&D, AstraZeneca, Gothenburg, 43150, Sweden.
  • Esbjörner EK; Discovery Sciences, R&D, AstraZeneca, Gothenburg, 43150, Sweden.
  • Collén A; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14157, Sweden.
  • El Andaloussi S; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden.
Commun Biol ; 5(1): 185, 2022 03 01.
Article em En | MEDLINE | ID: mdl-35233031
ABSTRACT
The therapeutic and research potentials of oligonucleotides (ONs) have been hampered in part by their inability to effectively escape endosomal compartments to reach their cytosolic and nuclear targets. Splice-switching ONs (SSOs) can be used with endosomolytic small molecule compounds to increase functional delivery. So far, development of these compounds has been hindered by a lack of high-resolution methods that can correlate SSO trafficking with SSO activity. Here we present in-depth characterization of two novel endosomolytic compounds by using a combination of microscopic and functional assays with high spatiotemporal resolution. This system allows the visualization of SSO trafficking, evaluation of endosomal membrane rupture, and quantitates SSO functional activity on a protein level in the presence of endosomolytic compounds. We confirm that the leakage of SSO into the cytosol occurs in parallel with the physical engorgement of LAMP1-positive late endosomes and lysosomes. We conclude that the new compounds interfere with SSO trafficking to the LAMP1-positive endosomal compartments while inducing endosomal membrane rupture and concurrent ON escape into the cytosol. The efficacy of these compounds advocates their use as novel, potent, and quick-acting transfection reagents for antisense ONs.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Oligonucleotídeos Antissenso Idioma: En Revista: Commun Biol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Oligonucleotídeos Antissenso Idioma: En Revista: Commun Biol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia